For patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), the combination of anastrozole, palbociclib, trastuzumab, and pertuzumab shows promise, according to a study published online July 30 in the Journal of the National Cancer Institute.
Rima Patel, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues evaluated frontline anastrozole, palbociclib, trastuzumab, and pertuzumab in patients with HR-positive, HER2-positive MBC. Patients received escalating doses of palbociclib with trastuzumab, pertuzumab, and anastrozole in phase 1, with a primary endpoint of maximum tolerated dose (MTD). In phase 2, all patients received palbociclib at the MTD, plus anastrozole, trastuzumab, and pertuzumab; the primary endpoint was clinical benefit rate (CBR) in the first six months.
The researchers found no dose-limiting toxicities at the 100- or 125-mg dose levels (three and six patients, respectively); the MTD was established as 125 mg. Phase 2 enrolled an additional 23 patients, yielding a response-evaluable population of 29 patients. The primary endpoint was 97 percent for CBR. Median progression-free survival was 24.9 months at a median follow-up of 45.3 months. At follow-up of 39.4 months, median overall survival was not reached. Neutropenia, leukopenia, diarrhea, and anemia were the most common treatment-related adverse events (TRAEs); 62 percent of patients had grade 3 TRAEs, most of which were hematologic.
“Although these findings need to be confirmed in larger randomized clinical trials, they suggest that some patients may eventually have an effective alternative to chemotherapy as their first treatment,” coauthor Amy Tiersten, M.D., also from the Icahn School of Medicine at Mount Sinai, said in a statement.
Pfizer provided palbociclib and funding for the clinical trial.
Black women have a 40 percent higher breast cancer mortality rate than white women, despite having a lower overall incidence. They are also more likely to be diagnosed with more aggressive disease and at younger ages, factors that can complicate treatment decisions.
As treatment increasingly moves toward precision medicine, the benefits of new targeted approaches will partly depend on whether all eligible patients have equitable access to:
A chemo-free treatment regimen could eventually be particularly meaningful if it reduces treatment burden without sacrificing efficacy, but these findings still need further evaluation before they become part of clinical practice.
The findings reinforce the growing importance of identifying the specific molecular or genetic drivers of the cancer. There’s an increasing role of biomarker-driven treatment selection in metastatic breast cancer, giving patients more personalized treatment plans. However, access to timely, comprehensive testing matters as treatment options become more complex.
Several disparities in genomic/molecular testing and precision oncology exist, including:
With these barriers in mind, clinicians must ensure that Black and minority patients are not left behind as oncology moves toward increasingly personalized treatment strategies.
Black Americans have been historically underrepresented in clinical trials, which can make it difficult for researchers and clinicians to determine whether the findings are equally applicable across diverse populations.
As multi-drug targeted regimens move forward into larger trials, having diverse participants can be beneficial for understanding:
Clinicians can play a major role in improving representation in medical research by discussing clinical trial opportunities with eligible patients and addressing barriers that may prevent participation.
While the study’s results show promise, chemotherapy still remains an important treatment for many patients with metastatic breast cancer. A chemo-free treatment approach could be appealing if future studies confirm it is comparable or delivers improved outcomes. Given the well-known adverse effects of chemotherapy and its associated burdens, a combo targeted therapy regimen could have some advantages. However, researchers are still investigating this combination treatment, so it should not yet be interpreted as a replacement for established standards of care.
Abstract/Full Text (subscription or payment may be required)
By subscribing, you consent to receive emails from BlackDoctor.pro You may unsubscribe at any time. Privacy Policy & Terms of Service.
Are you a healthcare professional? Register with us today!
